subscribeSubscribe
BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer

BMS gains EMA validation for Opdivo/Yervoy combo in liver cancer
PRESS RELEASE
20 Jul 2024
Share Share
Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy

Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy
BUSINESSWIRE
19 Jul 2024
Share Share
ASCO: Bristol calls Roche and AZ`s bets in 1L liver cancer

ASCO: Bristol calls Roche and AZ`s bets in 1L liver cancer
Angus Liu FIERCE PHARMA
04 Jun 2024
Share Share
BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma

BMS` triplet, Iovance`s Amtagvi-Keytruda target melanoma
Angus Liu FIERCE PHARMA
24 May 2024
Share Share
EMA Validates BMS’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab)

EMA Validates BMS’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab)
PRESS RELEASE
06 May 2024
Share Share
Bristol Myers Squibb`s Opdivo application validated by EMA.

Bristol Myers Squibb`s Opdivo application validated by EMA.
BUSINESSWIRE
06 May 2024
Share Share
Ultimovacs lays off 40% in wake of cancer vaccine`s phase 2 fail

Ultimovacs lays off 40% in wake of cancer vaccine`s phase 2 fail
James Waldron FIERCE BIOTECH
17 Apr 2024
Share Share
Bristol Myers` Opdivo-Yervoy combo meets main goal in liver cancer trial

Bristol Myers` Opdivo-Yervoy combo meets main goal in liver cancer trial
REUTERS
21 Mar 2024
Share Share
Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination

Ultimovacs Announces Results from INITIUM Study Evaluating UV1 Vaccination
GLOBENEWSWIRE
07 Mar 2024
Share Share
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
BUSINESSWIRE
22 Jan 2024
Share Share